IMUNON announced that its new DNA-based immunotherapy for advanced ovarian cancer has shown encouraging results in the ...

New data for darolutamide confirm safety and improved efficacy across subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) by 40% and 70% respectively, compared to placebo ...